Executive Wealth Management LLC Sells 22,839 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Executive Wealth Management LLC lowered its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 23.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,700 shares of the biopharmaceutical company's stock after selling 22,839 shares during the period. Executive Wealth Management LLC's holdings in Royalty Pharma were worth $2,113,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. M&G Plc purchased a new position in shares of Royalty Pharma during the 2nd quarter worth $447,000. PGGM Investments grew its stake in shares of Royalty Pharma by 2.7% during the second quarter. PGGM Investments now owns 91,855 shares of the biopharmaceutical company's stock valued at $2,422,000 after acquiring an additional 2,385 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Royalty Pharma during the second quarter valued at about $254,000. Swedbank AB grew its stake in shares of Royalty Pharma by 30.6% during the second quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company's stock valued at $285,151,000 after acquiring an additional 2,533,570 shares in the last quarter. Finally, Gladius Capital Management LP acquired a new stake in shares of Royalty Pharma during the second quarter valued at about $32,000. Institutional investors and hedge funds own 54.35% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. The Goldman Sachs Group lifted their price target on Royalty Pharma from $50.00 to $51.00 and gave the stock a "buy" rating in a research note on Wednesday, August 14th. StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, November 5th. Finally, Citigroup lowered their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday, October 25th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, Royalty Pharma has a consensus rating of "Moderate Buy" and an average target price of $41.67.

Royalty Pharma Stock Down 1.6 %

Shares of RPRX stock traded down $0.42 on Tuesday, hitting $25.59. The company's stock had a trading volume of 3,130,272 shares, compared to its average volume of 2,649,697. The stock has a market capitalization of $15.08 billion, a price-to-earnings ratio of 13.26, a P/E/G ratio of 4.55 and a beta of 0.46. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. Royalty Pharma plc has a fifty-two week low of $25.10 and a fifty-two week high of $31.66. The firm's fifty day moving average price is $26.94 and its 200-day moving average price is $27.27.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 3.28%. The ex-dividend date is Friday, November 15th. Royalty Pharma's dividend payout ratio is 43.52%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.